Healthcare

Latest Guidebook for Chinese In-vitro Diagnostic Reagent GMP Regulations

  • ACC358387
  • 134 Pages
  • November 2015
  • Healthcare
Summery

China has an indispensable in-vitro diagnostic reagent market for overseas and multinational in-vitro diagnostic reagent companies. Chinese healthcare market has maintained annually average growth rate above 16 % since 1990s. Among them, in-vitro diagnostic reagents represented dynamical growth since 2007. By 2014, total value of in-vitro diagnostic reagents on Chinese healthcare market has reached 4.3 billion US dollars. The in-vitro diagnostic reagents have been widely used in the process of disease prevention, diagnosis, treatment monitoring, prognosis observation, health status evaluation and inherited disease prediction. On the Chinese in-vitro diagnostic reagent market, imported overseas in-vitro diagnostic reagents made by overseas and multinational in-vitro diagnostic reagent manufacturers accounted for about a half, in which the high-tech and high-valued in-vitro diagnostic reagents are almost monopolized by the American Life Technologies, Roche, Abbott, Siemens, Beja Asian capital and other overseas and multinational companies. It is estimated that Chinese in-vitro diagnostic reagent market is likely to be more than 5.68 billion US dollars until 2015, and it is one of segment market of the most growth potentiality.

However, since October 2014, Chinese regulatory authorities have significantly changed the regulations on in-vitro diagnostic reagents. China Food and Drug Administration (CFDA) issued the latest Chinese Good Manufacturing Practice (GMP) for Medical Devices on December 29, 2014, which has come into force as March 1, 2015. On July 10, 2015, China Food and Drug Administration (CFDA) further issued the latest Implementation Regulations of Good Manufacturing Practice (GMP) for In--vitro Diagnosis Reagents as the appendices of the latest Chinese Good Manufacturing Practice (GMP) for Medical Devices, which has come into force as October 1, 2015. Furthermore, on September 25, 2015, China Food and Drug Administration (CFDA) issued the On-site Inspection Guideline of Good Manufacturing Practice (GMP) for Medical Devices, On-site Inspection Guideline for In--vitro Diagnosis Reagent GMP Implementation Regulations respectively. Everything changed.

China Food and Drug Administration (CFDA) requests that all the newly established in-vitro diagnostic reagent manufacturers, the existing in-vitro diagnostic reagent manufacturers to increase production of Class III in-vitro diagnostic reagents, the relocated in-vitro diagnostic reagent manufacturers or the in-vitro diagnostic reagent manufacturers to expand manufacturing sites should follow the requirements of the latest Good Manufacturing Practice (GMP) Regulations for Medical Devices and the latest Implementation Regulations of Good Manufacturing Practice (GMP) for In--vitro Diagnosis Reagents. Since January 1, 2016, the in-vitro diagnostic reagent manufacturers to manufacture Class III in-vitro diagnostic reagents must comply with the the requirements of the latest Good Manufacturing Practice (GMP) Regulations for Medical Devices and the latest Implementation Regulations of Good Manufacturing Practice (GMP) for In--vitro Diagnosis Reagents. Since January 1, 2018, all the in-vitro diagnostic reagent manufacturers must comply with the requirements of the latest Good Manufacturing Practice (GMP) Regulations for Medical Devices and the latest Implementation Regulations of Good Manufacturing Practice (GMP) for In--vitro Diagnosis Reagents.Those manufacturers that do not meet those deadlines may face enforcement actions by the food and drug regulatory authorities.

At present, overseas and multinational in-vitro diagnostic reagent manufacturers, as well as domestic in-vitro diagnostic reagent manufacturers are confronting with multiple inspection and verification of GMP rules and the relevant assorted GMP implementation regulations. The overseas in-vitro diagnostic reagent manufacturers exporting Class II and Class III overseas in-vitro diagnostic reagents into Chinese in-vitro diagnostic reagent market, they must be subject to examination and approval of registration license, as well as the inspection and verification of GMP rules by the CFDA directly under the State Council. The multinational in-vitro diagnostic reagent manufacturers have penetrated into the Chinese in-vitro diagnostic reagent market, their affiliated manufacturers within territory of China must be subject to not only the examination and approval of registration license and production license, as well as on-site inspection and verification of GMP rules and the relevant assorted GMP implementation regulations, but also on-site inspections of GMP rules for various supervisions and enforcements, such as the routine supervision and enforcement, the follow-up supervision and enforcement, the surprise spot-check for special issues, and so on.

The on-site inspection of GMP rules and the relevant assorted GMP implementation regulations is an extremely stringent inspection and verification process of GMP rules and the relevant assorted GMP implementation regulations for in-vitro diagnostic reagent manufacturing enterprise. The regulatory authorities will dispatch the inspection team to conduct the on-site inspection by the manner of article to article, clause to clause in accordance with the GMP rules and the relevant assorted GMP implementation regulations to verify whether the in-vitro diagnostic reagent manufacturing enterprise is compliance with the GMP rules and the relevant assorted GMP implementation regulations.

How do you in compliance with the latest Chinese in-vitro diagnostic reagent GMP regulations? How do you operate business smoothly in China? The overseas and multinational in-vitro diagnostic reagent manufacturers and their senior executive officers engaging in regulatory affairs must have a comprehensive and thorough knowledge of the latest Chinese in-vitro diagnostic reagent GMP regulations. Otherwise, the restrictive legal requirements and approval delays will eat up your time and energy to achieve a successful entry into such a lucrative in-vitro diagnostic reagent market, and cause trouble for your business smoothly in China.

Latest Guidebook for Chinese In-vitro Diagnostic Reagent GMP Regulations is an essential resource for overseas and multinational in-vitro diagnostic reagent manufacturers to achieve a successful entry into the Chinese in-vitro diagnostic reagent market, and to operate business smoothly in China, which provides not only a comprehensive and thorough knowledge of the latest Chinese In-vitro Diagnostic Reagent GMP Regulations, but also the practical operation how to comply with the latest Chinese In-vitro Diagnostic Reagent GMP Regulations, how to smoothly pass throug the extremely stringent on-site inspection and verification process of GMP rules and the relevant assorted GMP implementation regulations.

The organizations of this guidebook are arranged as follows. Chapter 2 provides an overview of organizational structure of Chinese regulatory authorities for In-vitro Diagnostic Reagent GMP regulations. Chapter 3 provides an overview of Good Manufacturing Practice (GMP) for Medical Devices, which are comprehensive regulations to regulate a manufacturers quality management system throughout the process from design, development and manufacturing to sales and after-sales service. Chapter 4 introduces the detailed Implementation Regulations of Good Manufacturing Practice (GMP) for In-vitro Diagnostic Reagents. Chapter 5 elaborates the on-site inspection of Good Manufacturing Practice (GMP) for in-vitro diagnostic reagents to smoothly navigate complex regulatory requirements step by step. Chapter 6 elaborates the on-site inspection items and contents of Good Manufacturing Practice (GMP) for in-vitro diagnostic reagents to help overseas and multinational in-vitro diagnostic reagent companies to understand extraordinarily complex inspection requirements by article to article and clause to clause.

The audiences of this guidebook are overseas in-vitro diagnostic reagent manufacturers wishing to enter into the Chinese in-vitro diagnostic reagent market, and multinational in-vitro diagnostic reagent companies have penetrated into the Chinese in-vitro diagnostic reagent market, and their senior executive officers engaging in regulatory affairs expecting to understand how to apply for registration license or production license of their in-vitro diagnostic reagent products in China, how to comply with the latest Chinese in-vitro diagnostic reagent GMP regulations, how to smoothly pass throug the extremely stringent on-site inspection and verification process of GMP rules and the relevant assorted GMP implementation regulations.

After having skimmed through this guidebook, audiences can clearly acquire not only a comprehensive and thorough knowledge of the latest Chinese in-vitro diagnostic reagent GMP regulations but also the practical operation how to comply with the latest Chinese in-vitro diagnostic reagent GMP regulations. Access China Management Consulting Ltd hopes this guidebook, based on full and accurate regulations, can guide overseas and multinational in-vitro diagnostic reagent manufacturers and their senior executive officers engaging in regulatory affairs to achieve a successful entry into the Chinesein-vitro diagnostic reagent market, and to smoothly operate their products in China.

Report Highlights

An overview of organizational structure of Chinese regulatory authorities for medical device GMP regulations.
An overview of Good Manufacturing Practice (GMP) for Medical Devices, which are comprehensive regulations to regulate a manufacturers quality management system covering the entire process from design, development and manufacturing to sales and after-sales service.
The detailed Implementation Regulations of Good Manufacturing Practice (GMP) for In-vitro Diagnostic Reagents.
The overall provisions of on-site inspection and verification of Good Manufacturing Practice (GMP) for in-vitro diagnostic reagents to smoothly navigate complex regulatory requirements step by step.
The comprehensive and detailed on-site inspection items and contents of Good Manufacturing Practice (GMP) for In-vitro Diagnostic Reagents to help overseas and multinational in-vitro diagnostic reagent companies to understand extraordinarily complex inspection requirements by article to article and clause to clause.

Reason to Buy

China has an indispensable in-vitro diagnostic reagent market for overseas and multinational in-vitro diagnostic reagent companies. Its definitely a field worth playing on, but Chinese regulatory framework for in-vitro diagnostic reagents has undergone significantly changed. Since October 2014, Chinese regulatory authorities have significantly changed the regulations on in-vitro diagnostic reagents. China Food and Drug Administration (CFDA) issued the latest Chinese Good Manufacturing Practice (GMP) for Medical Devices on December 29, 2014, which has come into force as March 1, 2015. On July 10, 2015, China Food and Drug Administration (CFDA) further issued the latest Implementation Regulations of Good Manufacturing Practice (GMP) for In--vitro Diagnosis Reagents as the appendices of the latest Chinese Good Manufacturing Practice (GMP) for Medical Devices, which has come into force as October 1, 2015. Furthermore, on September 25, 2015, China Food and Drug Administration (CFDA) issued the On-site Inspection Guideline of Good Manufacturing Practice (GMP) for Medical Devices, On-site Inspection Guideline for In--vitro Diagnosis Reagent GMP Implementation Regulations respectively. Everything changed.

Facing sharp changes of in-vitro diagnostic reagent GMP regulations, how do you in compliance with the latest Chinese in-vitro diagnostic reagent GMP regulations? How do you operate business smoothly in China? The overseas and multinational in-vitro diagnostic reagent manufacturers and their senior executive officers engaging in regulatory affairs must have a comprehensive and thorough knowledge of the latest Chinese in-vitro diagnostic reagent GMP regulations. Otherwise, the restrictive legal requirements and approval delays will eat up your time and energy to achieve a successful entry into such a lucrative in-vitro diagnostic reagent market, and cause trouble for your business smoothly in China.

Latest Guidebook for Chinese In-vitro Diagnostic Reagent GMP Regulations is an essential resource for overseas and multinational in-vitro diagnostic reagent manufacturers to achieve a successful entry into the Chinese in-vitro diagnostic reagent market, and to operate business smoothly in China, which provides not only a comprehensive and thorough knowledge of the latest Chinese In-vitro Diagnostic Reagent GMP Regulations, but also the practical operation how to comply with the latest Chinese In-vitro Diagnostic Reagent GMP Regulations, how to smoothly pass throug the extremely stringent on-site inspection and verification process of GMP rules and the relevant assorted GMP implementation regulations. It is worth for overseas and multinational medical device manufacturers and their senior executive officers engaging in regulatory affairs reading on.
Please Select Format

Enquiry About Report

Need More Information

Contact us
+ 1-800-910-6452
+1-971-202-1575
+91 20 66346066
--- or ---
help@bigmarketresearch.com

 

UPCOMING MARKET RESEARCH REPORTS

U.S. NPWT Devices Market - Opportunities and Forecast, 2015 - 2020

Negative Pressure Wound Therapy (NPWT) devices are used to heal wounds by applying sub-atmospheric pressure using sealed dressing connected to vacuum pump. The vacuum source generates negative pressure to remove ...

July 2017 | $2850 | Pre Book Price:$2494

Asian Chromatography Solvents Market - Opportunities and Forecasts, 2015 - 2020

Chromatography is a technique used for separation of mixtures for advanced use. Chromatography solvents, such as methanol, chloroform, ethanol, and others are used for separation of mixtures. One component solvent ...

July 2017 | $2850 | Pre Book Price:$2494

Intra-Dialytic Hypotension (IDH) Asia-Pacific Market Research Report, 2013 - 2020

Intra-dialytic hypotension (IDH) is defined as a fall in systolic blood pressure by ≥20 mmHg or in mean arterial pressure (MAP) by 10 mmHg correlated with symptoms, which include nausea, ...

July 2017 | $2850 | Pre Book Price:$2494

Asia Colonoscopy Devices Market - Opportunities and Forecasts, 2014 - 2020

Colonoscopy devices are used for internal examination of large intestine or colon as well as rectum. These devices come with a small camera connected to a flexible tube. Furthermore, the ...

July 2017 | $2850 | Pre Book Price:$2494

European Dermatology Diagnostic Devices Market- Opportunities and Forecasts, 2014 - 2020

The healthcare sector across Europe is witnessing a dramatic shift and is inclined towards less invasive diagnostic procedures. Dermatology diagnostic equipment aids in both easy as well as painless diagnosis. ...

July 2017 | $3390 | Pre Book Price:$2967

Asia Pacific Spine Surgery Devices Market - Opportunities and Forecasts, 2015 - 2020

Spine surgery devices are used in surgeries performed for treatment of spinal cord disorders, trauma, bleeding, tumors and others. These devices are used for the treatment of spinal disorders, such ...

July 2017 | $2850 | Pre Book Price:$2494

2017 © Copyright Big Market Research

View Pricing >>